MD, University of Maryland School of Medicine
Residency and Fellowship, University of Vermont School of Medicine, Washington VA Medical Center
Co-PI of the Chicago Women’s Interagency HIV Study (WIHS), a 20+ year longitudinal, observation study of HIV-infected and demographically similar uninfected women.
PI of WIHS-nested R01- Contribution of Sleep and Circadian Disruption to Kynurenine Pathway Activation and Cardiometabolic Risk in Women with HIV.
PI of Keeping it LITE: Exploring HIV Risk in Vulnerable Youth with Limited Interaction, a virtual cohort of young and very young sexual minorities in Chicago.
Areas of Expertise: HIV in Women, HIV Prevention, HIV and Viral Hepatitis, HIV-related medical comorbidities
R01 HL142116 French/Burgess (PIs) 5/1/18-4/30/22
NIH/NHLBI
The Contribution of Sleep and Circadian Disruption to Kynurenine Pathway Activation and Cardiometabolic Risk in Women with HIV
The major goal of this project is to study the mechanistic pathway between sleep and Circadian disruption and cardiovascular risk in HIV-infected women.
Role: PI
UG3 AI33676 French/Hosek (PIs) 7/21/17-7/20/22
NIH/NIAID/NICHD
Keeping it Lite: Exploring HIV Risk in Vulnerable Youth with Limited Interaction
The major goal of this project is to articulate the risk environment in which young men who have sex with men and transgender women are acquiring HIV in Chicago.
Role: PI
U01 AI34993 Cohen/French (PIs) 12/1/12-12/31/18
NIH/NIAID/NCI/NIDA
The Chicago WIHS Consortium for the Comprehensive Study of Women Living with HIV (WIHS-V)
The major goals of this project are to determine the spectrum and course of HIV infection in women during the HAART era.
Role: PI
Competitive supplement to U01 AI34993
NIH/NIAID/NCI/NIDA
Immunologic and Clinical Consequences of Hepatitis C Cure
The major goal of the project is to articulate neurocognitive outcomes of hepatitis C cure and correlate with markers of macrophage activation.
Role: PI
DMID 14-0029 French (Site PI)
DMID Sexually Transmitted Infections Clinical Trial Group
The purpose of the CTG is to provide a platform for clinical trials of novel agents to treat and prevent sexually transmitted infections.
Role: Site PI